KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-center, randomized, vehicle-controlled, double-blinded,
parallel-group study.
Approximately 6 sites will conduct the study at Germany. Approximately 61 patients (male and
female) planned to be screened. 51 patient planned to be randomized.
Patients will be randomized to 1 of 3 treatment arms (KM-001 0.3%, KM-001 1%, or vehicle
cream) iina a ration of 1:1:1
Patient's duration of participation will be up to 7 weeks,
- a screening period with 1 visit (Visit 1) within up to 14 days (Days -14 to -1),
- a 4-week treatment period with 3 visits (Visit 2 on Day 0, Visit 3 on Day 7, Visit 4 at
Day 28 and 2 phone calls on Days 14 and 21, and
- a 1-week follow-up period with 1 visit (Visit 5 on Day 35), as well as unscheduled
visits as needed
Since KM-001 is tested in humans for the first time, the safety of KM-001 will be evaluated
in a subgroup of 6 patients (sentinel group) at selected sites prior to screening of the
remaining sites.
Efficacy assessments will include subjective assessments of itch and investigator assessment
of the treatment effect on LSC target lesion using scoring systems.
Safety parameter (including physical examination, vital signs, ECG, standard laboratory test,
and PK analysis) will be monitored from the signing of the informed consent form (ICF) until
the last follow-up visit. Recording of AEs and serious AEs (SAEs) will be done throughout the
study with special attention to local AEs in the treatment area (LSC target lesion, dermal
safety).